Active Biotech provides status update in the portfolio projects
Lund, June 3, 2020 - Active Biotech (Nasdaq Stockholm: ACTI) today provides a status update in the projects following the new direction communicated in early February. This abbreviated update is provided as a midterm replacement of the Capital Markets Day previously announced for May 19, which we now instead are planning to host during Q4 this year subject to the status of Covid-19. Despite the Covid-19 pandemic, most activities in our projects have proceeded according to plan and, so far, no project timelines have been significantly affected.
The Phase 1b/2 study with naptumomab in combination with the checkpoint inhibitor durvalumab in patients with advanced solid tumors aims to establish the maximum tolerated dose of the combination before advancing to a larger cohort expansion phase in the United States. The study is enrolling according to plan and we look forward to reviewing results from the dose escalation phase of this trial later this year.
In the tasquinimod project, which is directed towards multiple myeloma, the final preparations to start the first clinical study with tasquinimod in this indication are underway. The study, which is planned to recruit up to 54 patients, will establish a maximum tolerated dose of tasquinimod alone, then investigate tasquinimod in combination with a standard multiple myeloma oral regimen of ixazomib, lenalidomide, and dexamethasone. For both single agent tasquinimod and the combination with the standard oral treatments, exploratory expansion cohorts will be enrolled to preliminarily characterize the anti-myeloma activity of each regimen. The Covid-19 pandemic has slowed down trial initiation procedures during April and May, but our advanced preparations enable us to maintain the target of first patient recruited into the study during the third quarter of this year, as previously communicated. More detailed information about the study is available on clinicaltrials.gov (NCT04405167).
New preclinical data on the effects of tasquinimod in experimental models of multiple myeloma, will be presented at the Virtual edition of the European Hematology Association Meeting – EHA, in June 11-22. Data to be presented include effects of tasquinimod alone and in combination with treatments from the compound classes that will be used in the upcoming clinical study, i.e. immunomodulatory drugs (IMiDs)and proteasome inhibitors (PIs). This work has been completed in collaboration with Dr Yulia Nefedova and her team at the Wistar Institute, Philadelphia, US. The data will be made available through activebiotech.com in connection with the presentation.
In the laquinimod project, which now is directed into a project focused towards systemic treatment of Crohn’s disease, and a project focused towards topical development of a new treatment for the eye diseases uveitis and wet AMD, progress has also been realized. We have entered into an agreement with Leukocare AG, who has expertise in formulation development to support our work in advancing a topical formulation. In parallel we have identified partners to further expand our preclinical data of laquinimod in advanced pre-clinical models of the eye-disorders in focus. In Crohn’s disease we are evaluating and compiling the documentation from the previous clinical phase 2a study results prior to a regulatory advice procedure with the FDA and EMA.
An abstract reporting on the effects of laquinimod in an experimental model of the blinding disease uveitis, accepted for presentation at the scientific meeting The American Association of Immunology, was recently published in the Journal of Immunology (J Immunol May 1, 2020, 204 (1 Supplement) 150.18). This study, performed by a research team at the National Eye Institute at the National Institute of Health in the US, demonstrated that laquinimod completely prevented disease development and inhibited pro-inflammatory processes in a mouse model of autoimmune uveitis. The abstract is available for downloading through www.activebiotech.com.
“I am very pleased with the progress we have achieved across our development projects since our new research focus was announced back in February this year. I now look forward to taking the next step with tasquinimod and starting the first clinical trial in multiple myeloma” says Helena Eriksson, Chief Scientific Officer at Active Biotech.
At the Annual General Meeting of Active Biotech held on May 19, 2020, the Board was further strengthened with the new Board members, Dr. Elaine Sullivan, Dr. Aleksandar Danilovski and Dr. Axel Glasmacher. All of the new Board members have broad international sector competences and extensive scientific insights in the areas that Active Biotech now is focusing on. Aleksandar brings expertise especially within the CMC and regulatory field. Axel will contribute with deep medical, clinical development and regulatory expertise specifically in the field of hematology, while Elaine, complements the Board with her broad experiences from roles within science leadership, business development and Executive management. All Board members will work alongside the Active Biotech team to support execution of the new direction.
“We welcome Elaine, Aleksandar and Axel to Active Biotech, they will be an important complement to the Board and to the Active Biotech team. Together we will form a strong lineup to advance the projects according to our new direction” says Helén Tuvesson, CEO of Active Biotech.
For further information, please contact:
Helén Tuvesson, CEO
Tel. +46 46 19 21 56
Hans Kolam, CFO
Tel +46 46 19 20 44
Active Biotech AB (publ) (NASDAQ Stockholm: ACTI) is a biotechnology company with focus on cancer and autoimmune/inflammatory diseases. Naptumomab, an immunotherapy licensed to NeoTX Therapeutics Ltd., is in clinical phase 1b/2 development for treatment of solid tumors, NCT03983954. Tasquinimod, an immunomodulator, is in development for treatment of multiple myeloma. Laquinimod, an immunomodulator, is evaluated as a potential treatment of the eye disorders wet AMD and uveitis and the inflammatory bowels disease, Crohn’s disease. Please visit www.activebiotech.com for more information.
Active Biotech AB
(Corp. Reg. No. 556223-9227)
Box 724, SE-220 07 Lund, Sweden
Tel: +46 (0)46 19 20 00
This information is information that Active Biotech AB is obliged to make public pursuant to the EU Market Abuse Regulation. This information was submitted for publication, through the agency of the contact person set out above, at 08.30 a.m. CET on June 3, 2020.
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire
Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire
Suominen Corporation – Manager’s transaction: Borgman, Björn7.7.2020 09:00:00 CEST | Press release
Suominen Corporation July 7, 2020 at 10:00 a.m. (EEST) Suominen Corporation - Managers' Transactions ____________________________________________ Person subject to the notification requirement Name: Borgman, Björn Position: Member of the Board/Deputy member Issuer: Suominen Corporation LEI: 743700Z1BNFYR9PRDF52 Notification type: INITIAL NOTIFICATION Reference number: 743700Z1BNFYR9PRDF52_20200706182550_2 ____________________________________________ Transaction date: 2020-07-06 Venue: NASDAQ HELSINKI LTD (XHEL) Instrument type: SHARE ISIN: FI0009010862 Nature of the transaction: ACQUISITION Transaction details (1): Volume: 4,037 Unit price: 3.9 EUR (2): Volume: 963 Unit price: 3.89 EUR Aggregated transactions (2): Volume: 5,000 Volume weighted average price: 3.89807 EUR SUOMINEN CORPORATION For more information, please contact Emilia Peltola, Vice President, Corporate Communications & IR, Suominen Corporation, tel. +358 50 540 9747 Suominen manufactures nonwovens as roll goods for wipe
Nokia accelerates availability of Open RAN technology to lead the open mobile future7.7.2020 09:00:00 CEST | Press release
Press Release Nokia accelerates availability of Open RAN technology to lead the open mobile future Nokia Open RAN (O-RAN) solutions will deliver world-class performance and security to the O-RAN ecosystemAvailability this year with full suite of O-RAN-defined interfaces expected in 2021. Combined with the recently announced Nokia's 5G AirScale Cloud RAN in vRAN 2.0 configuration, with full baseband in cloud, CSPs can build a flexible network architecture that maximizes performance, efficiency, and scalability Nokia's leadership in O-RAN R&D demonstrates commitment to an open innovation ecosystem and robust telecom supply chain Nokia is the only global RAN supplier fully committed to O-RAN with commercial 5G Cloud-RAN networks 7 July 2020 Espoo, Finland – Nokia today announced that it is enhancing its industry leadership in open solutions by rapidly ramping up the adoption of Open RAN (O-RAN) interfaces in its AirScale portfolio. This enhancement to its radio access network (RAN) portfo
CellaVision AB presents the second quarter for 20207.7.2020 08:20:00 CEST | Press release
CellaVision presents the second quarter for 2020 on July 16, at 11:00 CET The information was submitted to the public on July 7, 2020 at 8:20 CET CellaVision AB (publ) will publish the Interim report for the second quarter 2020 on July 16, 2020 at 8:20 CET. The report will be available at www.cellavision.com In connection with the release of the interim report analysts, investors and media are hereby invited to a telephone conference and audio webcast at 11:00 CET where Zlatko Rihter, President & CEO, will present and comment the report. The presentation will be in English via a conference call or audio webcast: https://tv.streamfabriken.com/cellavision-q2-2020 Phone number for the conference: SE: +46 8 566 42693 UK: +44 333 300 9267 US: +1 8 332 498 404 No pre-registration is required. Please dial in 5-10 minutes prior to the scheduled start time to facilitate a timely start. About CellaVision CellaVision is an innovative, global medical technology company that develops and sells its
CellaVision AB presenterar andra kvartalet för 20207.7.2020 08:20:00 CEST | Pressemelding
CellaVision presenterar andra kvartalet för 2020 den 16 juli kl. 11:00 Informationen lämnades för offentliggörande 2020-07-07 kl 08.20 Den 16 juli 2020 klockan 08:20 publicerar CellaVision AB (publ) delårsrapporten för andra kvartalet. Rapporten kommer att finnas tillgänglig på www.cellavision.se I samband med detta inbjuds analytiker, investerare och media till en audiosänd telefonkonferens samma dag kl 11:00 där VD och koncernchef, Zlatko Rihter, presenterar och kommenterar rapporten. Presentationen sker på engelska via en telefonkonferens eller audiosändning på: https://tv.streamfabriken.com/cellavision-q2-2020 Telefonnummer till konferensen: SE: +46 8 566 42693 UK: +44 333 300 9267 US: +1 8 332 498 404 Ingen föranmälan krävs. Vänligen ring in till konferensen 5-10 minuter före utsatt starttid för att underlätta att den startar på fastställd tid. Om CellaVision CellaVision är ett innovativt, globalt medicinteknikföretag som utvecklar och säljer ledande system för rutinanalys av blod
Ahold Delhaize share buyback update7.7.2020 08:00:00 CEST | Press release
Zaandam, the Netherlands, July 7, 2020 – Ahold Delhaize has repurchased 250,000 of Ahold Delhaize common shares in the period from June 29, 2020 up to and including July 3, 2020. The shares were repurchased at an average price of €24.07 per share for a total consideration of € 6.02 million. These repurchases were made as part of the €1 billion share buyback program announced on December 4, 2019. The total number of shares repurchased under this program to date is 23,946,050 common shares for a total consideration of €520.9 million. Download the share buyback transactions excel sheet for detailed individual transaction information from www.aholddelhaize.com/en/investors/share-information/share-buy-back-programs/ This press release is issued in connection with the disclosure and reporting obligation set out in Article 2(2) of the EU Regulation that contains technical standards for buyback programs
Xavier Pichon appointed CEO of Orange Belgium7.7.2020 08:00:00 CEST | Press release
Press release Brussels, July 7, 2020 Xavier Pichon appointed CEO of Orange Belgium The Board of Directors of Orange Belgium has decided to appoint Xavier Pichon to the position of CEO of Orange Belgium as from September 1st, 2020. Xavier Pichon has 20 years’ experience as an ExCom member in large corporations. He started his career in 1990 as Head of Finance of Bouygues’ affiliates, followed by an Audit & Consulting position at Calan Ramolino/Salustro Reydel before joining Orange in 1998 where he took up various positions, such as Chief Financial Officer of Orange France and Group Head of Investor Relations. His last role was Deputy CEO at Orange France, leading Finance, Strategy, Transformation and Development. There, he co-led one of the most successful transformations of an incumbent telco to date. He was President and Board member of different Orange affiliates. He joined the Boston Consulting Group (BCG) in October 2018 in Paris, then Sydney in Australia and was a core member of t